Results 21 to 30 of about 48,580 (292)

A novel three-colour fluorescence in situ hybridization approach for the detection of t(7;12)(q36;p13) in acute myeloid leukaemia reveals new cryptic three way translocation t(7;12;16) [PDF]

, 2013
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).The t(7;12)(q36;p13 ...
Vetter, M, Sabrina Tosi, Plekhanova, O, Fleischman, E, Grigory Tsaur, Tsaur, G, Harbott, J, Sokova, O, Jochen Harbott, Tosi, S, Elena Fleischman, Olga Sokova, Naiel, A, Michael Vetter, Olga Plekhanova, Abdulbasit Naiel   +15 more
core   +1 more source

Cervical vestibular evoked myogenic potentials in 3-month-old infants: Comparative characteristics and feasibility for infant vestibular screening

Frontiers in Neurology, 2022
ObjectiveWe compared the characteristics of air-conducted sound cervical vestibular evoked myogenic potential (ACS-cVEMP) and bone-conducted vibration cVEMP (BCV-cVEMP) among 3-month-old infants with normal hearing and sensorineural hearing loss (SNHL ...
Jiali Shen, Jiali Shen, Jiali Shen, Lu Wang, Lu Wang, Lu Wang, Xiaobao Ma, Xiaobao Ma, Xiaobao Ma, Zichen Chen, Jianyong Chen, Jianyong Chen, Jianyong Chen, Xueyan Wang, Kuan He, Kuan He, Kuan He, Wei Wang, Wei Wang, Wei Wang, Jin Sun, Jin Sun, Jin Sun, Qin Zhang, Qin Zhang, Qin Zhang, Min Shen, Min Shen, Min Shen, Xiangping Chen, Xiangping Chen, Xiangping Chen, Qing Zhang, Qing Zhang, Qing Zhang, Kimitaka Kaga, Maoli Duan, Maoli Duan, Jun Yang, Jun Yang, Jun Yang, Yulian Jin, Yulian Jin, Yulian Jin   +43 more
doaj   +1 more source

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

Clinical Case Reports, 2022
The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐
Xenofon Baraliakos, Styliani Tsiami, Sooraj Vijayan, Haewon Jung, Nick Barkham   +4 more
doaj   +1 more source

t(6;12)(q15;p13) [PDF]

, 2020
Review on t(6;12)(q15 ...
Gindina, Tatiana
core   +1 more source

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +1 more source

P13

, 2021
CCEP files for patient ...
Claire Perry (10873347)
core   +1 more source

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Gut and Liver, 2023
Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber   +9 more
doaj   +1 more source

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

mAbs, 2021
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological
HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet   +16 more
doaj   +1 more source

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

BMJ Open Gastroenterology, 2023
Background We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre.Methods All adult patients with ...
Alaa Alakkari, Christian Philipp Selinger, Tanya Clark, Gemma Burdge, Giacomo Broglio, Isabel Carbery, Dan Greer   +6 more
doaj   +1 more source

Novel venom-based peptides (P13 and its derivative—M6) to maintain self-renewal of human embryonic stem cells by activating FGF and TGFβ signaling pathways

Stem Cell Research & Therapy, 2020
Background In our previous study, a venom-based peptide named Gonearrestide (also named P13) was identified and demonstrated with an effective inhibition in the proliferation of colon cancer cells.
Rui Ma, Zhili Ren, Bin Li, Shirley W. I. Siu, Guokai Chen, Hang Fai Kwok   +5 more
doaj   +1 more source